Mast cell activation syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:24:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mast cell activation syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Masitinib for Patients with Severe Mast Cell Activation Syndrome Unresponsive to Treatment https://clinicaltrials.eu/trial/study-on-masitinib-for-patients-with-severe-mast-cell-activation-syndrome-unresponsive-to-treatment/ Wed, 29 Apr 2026 14:59:16 +0000 https://clinicaltrials.eu/trial/study-on-masitinib-for-patients-with-severe-mast-cell-activation-syndrome-unresponsive-to-treatment/ This clinical trial is focused on studying a condition known as Mast Cell Activation Syndrome (MCAS). This is a disorder where certain cells in the body, called mast cells, release too many chemicals, leading to symptoms like skin rashes, flushing, and abdominal pain. The trial will test a medication called masitinib, which is a type of drug known as a tyrosine kinase inhibitor. This medication is taken orally in the form of a coated tablet.

The purpose of the study is to evaluate how effective and safe masitinib is compared to a placebo in treating patients with severe MCAS who have not responded well to other treatments. The study will last for 24 weeks, during which participants will be randomly assigned to receive either masitinib or a placebo. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo until the study is completed.

Throughout the study, participants will have regular check-ups to monitor their response to the treatment and any side effects. The main goal is to see if there is a significant improvement in symptoms such as itching, flushing, depression, and fatigue by the end of the 24 weeks. This trial aims to provide valuable information on whether masitinib can be a beneficial treatment option for those suffering from severe MCAS.

]]>